The DOI matches its Crossref record.
Linezolid, the first oxazolidinone antibacterial agent
Abstract
Linezolid (Zyvox™) is the first member of an entirely new class of antibiotics to reach the market in over 35 years; it was approved for use in 2000. A member of the oxazolidinone class of antibiotics, linezolid is highly effective for the treatment of serious Gram‐positive infections and has activity that compares favorably with vancomycin for most clinically relevant pathogens. Zyvox is approved for use against serious Gram‐positive infections, including those caused by Streptococcus pneumoniae, and the very challenging methicillin‐resistant Staphylococcus aureus and vancomycin‐resistant Enterococcus faecium organisms. Zyvox inhibits bacterial protein synthesis by binding to 23S rRNA in the catalytic site of the 50S ribosome. It can be administered both orally and intravenously and has good tissue distribution. Recent results have demonstrated that oxazolidinone analogs related to linezolid are effective in treating pulmonary tuberculosis caused by resistant Mycobacterium tuberculosis in animal infection models and suggest additional new therapeutic applications for these antibiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ribosome-targeting antibiotics and mechanisms of bacterial resistance
Wilson, D. N. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3155 · Cited by 1,054
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Lee, M., Lee, J., Carroll, M. W., Choi, H., Min, S., Song, T., Via, L. E., Goldfeder, L. C., Kang, E., Jin, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201964 · Cited by 560
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future
Rodvold, K. A., & McConeghy, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit614 · Cited by 358
Antibiotic Discovery: Where Have We Come from, Where Do We Go?
Ribeiro da Cunha, B., Fonseca, L. P., & Calado, C. R. C. (2019) · Antibiotics · doi:10.3390/antibiotics8020045 · Cited by 353
Metadata
- Authors
- Leach, K. L., Brickner, S. J., Noe, M. C., & Miller, P. F.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2011-03
- Volume
- 1222
- Issue
- 1
- Pages
- 49-54
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1947810765
- Cited by
- 195
- References
- 0
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Linezolid, the first oxazolidinone antibacterial agent. https://app.cochat.ai/papers/10.1111/j.1749-6632.2011.05962.x
- The paper
- Leach, K. L., Brickner, S. J., Noe, M. C., & Miller, P. F. (2011). Linezolid, the first oxazolidinone antibacterial agent. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2011.05962.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.